Lansoprazole + DomperidoneThird Party Manufacturing in India

This fixed-dose combination targets gastroesophageal reflux disease through two complementary mechanisms. Lansoprazole, a proton pump inhibitor, accumulates in the acidic canaliculus of gastric parietal cells, undergoes conversion to its active sulphenamide form, and forms covalent bonds with the H⁺/K⁺ ATPase enzyme. This irreversible inhibition shuts down the final step of gastric acid secretion, raising intragastric pH above 4 for most of the day. Domperidone, a benzimidazole derivative, acts as a peripheral dopamine D₂ receptor antagonist. Unlike metoclopramide, Domperidone does not readily cross the blood-brain barrier, making it less likely to cause extrapyramidal side effects. Its prokinetic action increases lower oesophageal sphincter pressure, enhances gastric peristalsis, and accelerates gastric emptying. This combined effect reduces both acid reflux episodes and the volume of refluxate. Domperidone also coordinates antroduodenal motility and has antiemetic properties through dopamine receptor blockade in the chemoreceptor trigger zone outside the blood-brain barrier. The synergy between acid suppression and prokinetic activity makes this combination particularly effective in patients who fail monotherapy with a PPI alone.

Therapeutic Uses

Lansoprazole + Domperidone is prescribed for the treatment of:

• Gastroesophageal Reflux Disease with Dysmotility: Particularly in patients with reflux symptoms accompanied by bloating, early satiety, or delayed gastric emptying.
• Non-Erosive Reflux Disease (NERD): Symptomatic relief in patients with reflux symptoms but without endoscopic oesophagitis.
• Functional Dyspepsia with Reflux Components: Where epigastric pain or burning occurs alongside regurgitation or heartburn.
• Gastroparesis-Related GERD: In diabetic or idiopathic gastroparesis where impaired gastric emptying contributes to reflux.
• Chronic Gastritis: Symptomatic management of epigastric discomfort associated with hyperacidity and dysmotility.

Why Manufacturers Choose Lansoprazole + Domperidone

This fixed-dose combination addresses a large and growing patient population who do not achieve adequate symptom control with a PPI alone. The combination is particularly popular in Indian and Asian markets where dyspepsia and bloating are commonly reported alongside classical reflux symptoms. Manufacturers benefit from the established API base for both molecules and well-characterised bilayer or monolithic tablet technologies that ensure stability of the acid-labile Lansoprazole component alongside Domperidone. The regulatory pathway is straightforward in most emerging markets as both active ingredients have extensive safety histories and are listed in national essential medicines lists.

This makes Lansoprazole + Domperidone one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.